Argomento

#merck

2 notizie

#pharmaceuticals #earnings #healthcare #moderna #cancer-vaccine #biotech

Merck & Co., Inc. (MRK) Shareholder/Analyst Presentation - Slideshow (NYSE:MRK) 2026-10-26

Merck & Co. has published an updated shareholder and analyst presentation detailing its strategic outlook and pharmaceutical pipeline. The report highlights core therapeutic areas, oncology developments, and commercial product performance. Investors are evaluating the updates for insights into revenue growth and pipeline progression.

3,4K2259

Azioni·2 settimane fa

I medici definiscono i dati sul vaccino contro il cancro di Moderna e Merck un grande passo avanti, nonostante la reazione di Wall Street

Moderna and Merck's melanoma vaccine data has received significant praise from medical specialists despite a muted market response. The results represent a clinically meaningful advancement for patients undergoing cancer surgery.

2,1K10911